{"preliminary_commentary":{"by_channel":{"x_thread":13},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03223155\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab","stereotactic body radiotherapy"]],"indication":"stage IV non-small cell lung cancer","name":"COSINR","nct_id":"NCT03223155","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cosinr-nct03223155. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"COSINR","arms":[{"description":"Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.","label":"Sequential Arm","type":"EXPERIMENTAL"},{"description":"Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).","label":"Concurrent Arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Stage IV Small Cell Lung Cancer"],"enrollment":{"count":78,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"DRUG"},{"name":"Stereotactic body radiation therapy","otherNames":["SBRT"],"type":"RADIATION"}],"last_update":"2026-03-04","lead_sponsor":"University of Chicago","official_title":"A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of serious adverse events","timeFrame":"Up to 4 years"}],"references":[{"citation":"Chen D, Wang L, Wen C, Piffko A, Bugno J, Yu X, Wang P, Ji F, Naccasha EZ, Wang J, Huang X, Chmura SJ, Pitroda SP, He C, Liang HL, Weichselbaum RR. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026 Jan 5;223(1):e20250641. doi: 10.1084/jem.20250641. Epub 2025 Nov 6.","pmid":"41196643","type":"DERIVED"}],"start_date":{"date":"2017-09-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03223155"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cosinr-nct03223155"}